NCT04916002: CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have had more than 5 lines of systemic therapy; Patients who have received previous CMP-001 treatment; Patients with untreated, symptomatic, or enlarging central nervous system metastases including leptomeningeal metastases

Comments are closed.

Up ↑